Fulcrum Therapeutics (NASDAQ:FULC) Now Covered by Analysts at Morgan Stanley

Share on StockTwits

Morgan Stanley began coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research note issued to investors on Monday morning, BenzingaRatingsTable reports. The firm issued an overweight rating and a $29.00 target price on the stock.

Separately, Bank of America initiated coverage on Fulcrum Therapeutics in a report on Monday. They issued a buy rating and a $19.00 price target on the stock.

Shares of Fulcrum Therapeutics stock opened at $9.26 on Monday. Fulcrum Therapeutics has a one year low of $9.25 and a one year high of $15.94.

In other news, major shareholder 6 Dimensions Capital, L.P. purchased 118,750 shares of the business’s stock in a transaction dated Monday, July 22nd. The shares were bought at an average cost of $16.00 per share, for a total transaction of $1,900,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mark J. Levin purchased 81,250 shares of the business’s stock in a transaction dated Monday, July 22nd. The stock was purchased at an average price of $16.00 per share, for a total transaction of $1,300,000.00. The disclosure for this purchase can be found here.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.

Featured Article: Dollar Cost Averaging

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

International Money Express  Stock Rating Reaffirmed by BTIG Research
International Money Express Stock Rating Reaffirmed by BTIG Research
Stephens Raises Good Times Restaurants  Price Target to $5.50
Stephens Raises Good Times Restaurants Price Target to $5.50
Guggenheim Begins Coverage on Genmab A/S
Guggenheim Begins Coverage on Genmab A/S
Online Resources  Receives New Coverage from Analysts at SunTrust Banks
Online Resources Receives New Coverage from Analysts at SunTrust Banks
Fulcrum Therapeutics  Now Covered by Analysts at Morgan Stanley
Fulcrum Therapeutics Now Covered by Analysts at Morgan Stanley
SunTrust Banks Boosts Manhattan Associates  Price Target to $92.00
SunTrust Banks Boosts Manhattan Associates Price Target to $92.00


© 2006-2019 Ticker Report